The initial success of the copyright undeniably transformed the drug landscape, but investing in companies heavily reliant on off-patent versions presents a challenging picture. Although early earnings were significant, the cessation of patents and the appearance of discounted alternatives have weakened sales. Thus, a thorough assessment of ongoing